Because regulation of post-ischemic inflammation in the brain and osteoclast activation in the bone are important in the treatment of ischemic stroke, targeting RANK signalling with this novel dually-effective peptide could be a promising approach, although further studies are needed to elucidate the molecular mechanisms of the anti-TLR2 and anti-TLR4 signalling as well as to discover how to stabilize the synthetic peptide for systemic administration. This evidence concerns the gene TLR4 and ischemic stroke.